WCLC2020: Pembrolizumab significantly improved 5-year survival in patients with previously treated advanced NSCLC

With more than 5 years of follow-up in the Keynote-010 study, pembrolizumab continued to provide clinically meaningful improvement in OS and PFS versus docetaxel in patients with previously treated, PD-L1–positive advanced NSCLC.